Cargando…

Correction: Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation

Detalles Bibliográficos
Autores principales:	Tang, Yong, Liu, Fenghua, Zheng, Chunning, Sun, Shaochuan, Jiang, Yingsheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3700868/ http://dx.doi.org/10.1186/1756-9966-32-42

Ejemplares similares

Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation
por: Tang, Yong, et al.
Publicado: (2012)

Correction: Clusterin confers gemcitabine resistance in pancreatic cancer
por: Chen, Qingfeng, et al.
Publicado: (2013)

Mesothelin regulates growth and apoptosis in pancreatic cancer cells through p53-dependent and -independent signal pathway
por: Zheng, Chunning, et al.
Publicado: (2012)

Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosis
por: Al Nakouzi, Nader, et al.
Publicado: (2016)

Correction: DUSP1 Is a Novel Target for Enhancing Pancreatic Cancer Cell Sensitivity to Gemcitabine
Publicado: (2014)

Correction to: Tenascin-c knockdown suppresses vasculogenic mimicry of gastric cancer by inhibiting ERK- triggered EMT
por: Kang, Xing, et al.
Publicado: (2021)

Correction: Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentiate the motility of pancreatic cancer cells
por: Li, Hehe, et al.
Publicado: (2023)

Inactivation of XPF Sensitizes Cancer Cells to Gemcitabine
por: George, Joseph W., et al.
Publicado: (2019)

Correction: A novel epigenetic modulating agent sensitizes pancreatic cells to a chemotherapy agent
por: Thakar, Manjusha, et al.
Publicado: (2020)

Correction: Identification of a novel bile marker clusterin and a public online prediction platform based on deep learning for cholangiocarcinoma
por: Gao, Long, et al.
Publicado: (2023)

Girdin Knockdown Increases Gemcitabine Chemosensitivity to Pancreatic Cancer by Modulating Autophagy
por: Wang, Sheng, et al.
Publicado: (2021)

Correction: eIF3f reduces tumor growth by directly interrupting clusterin with anti-apoptotic property in cancer cells
por: Lee, Ji-Yeon, et al.
Publicado: (2017)

Correction: Knockdown of DEC2 expression inhibits the proliferation of mesangial cells through suppressed glycolysis and p38 MAPK/Erk pathway in lupus nephritis
por: Qi, Huimeng, et al.
Publicado: (2023)

Clusterin confers gmcitabine resistance in pancreatic cancer
por: Chen, Qingfeng, et al.
Publicado: (2011)

Clinical significance of clusterin expression in pancreatic adenocarcinoma
por: Jin, Junshuo, et al.
Publicado: (2012)

Correction: Intracellular STING inactivation sensitizes breast cancer cells to genotoxic agents
por: Gaston, Julie, et al.
Publicado: (2019)

Correction to: Musashi2 promotes EGF-induced EMT in pancreatic cancer via ZEB1-ERK/MAPK signaling
por: Sheng, Weiwei, et al.
Publicado: (2020)

Correction: Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer
por: Wei, Lusheng, et al.
Publicado: (2021)

Correction: FIBP knockdown attenuates growth and enhances chemotherapy in colorectal cancer via regulating GSK3β-related pathways
por: Huang, Yan-Feng, et al.
Publicado: (2022)

Correction to: MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma
por: Xiong, Guangbing, et al.
Publicado: (2021)

Correction: A Ketogenic Diet in Combination with Gemcitabine Increases Survival in Pancreatic Cancer KPC Mice
por: Cortez, Natalia E., et al.
Publicado: (2022)

Correction: The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine
por: Jung, Deok-Beom, et al.
Publicado: (2019)

RNF7 knockdown inhibits prostate cancer tumorigenesis by inactivation of ERK1/2 pathway
por: Xiao, Yangjiong, et al.
Publicado: (2017)

Correction: UBE2T knockdown inhibits gastric cancer progression
por: Luo, Changjiang, et al.
Publicado: (2023)

Cytoplasmic Clusterin Suppresses Lung Cancer Metastasis by Inhibiting the ROCK1-ERK Axis
por: Huang, Shaobo, et al.
Publicado: (2022)

Timing of chemotherapy-induced neutropenia: the prognostic factor in advanced pancreatic cancer patients treated with gemcitabine / gemcitabine-based chemotherapy
por: Chen, Yang, et al.
Publicado: (2017)

Correction: Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma
por: Zhao, Tiansuo, et al.
Publicado: (2019)

Correction: Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 Phase 3 study
por: Guenther, Michael, et al.
Publicado: (2021)

Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer
por: Lim, Jae Yun, et al.
Publicado: (2015)

Correction for: CXCR4 knockdown enhances sensitivity of paclitaxel via the PI3K/Akt/mTOR pathway in ovarian carcinoma
por: Zi, Dan, et al.
Publicado: (2022)

Correction for: CXCR4 knockdown enhances sensitivity of paclitaxel via the PI3K/Akt/mTOR pathway in ovarian carcinoma
por: Zi, Dan, et al.
Publicado: (2023)

Correction to: HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation
por: Roca, Maria Serena, et al.
Publicado: (2022)

Expression of Concern to: Knockdown of ZFR suppresses cell proliferation and invasion of human pancreatic cancer
por: Zhao, Xiaolan, et al.
Publicado: (2018)

Correction: METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation
por: Lin, Chengjie, et al.
Publicado: (2023)

Correction: GATA2 Inhibition Sensitizes Acute Myeloid Leukemia Cells to Chemotherapy
por: Yang, Li, et al.
Publicado: (2017)

Correction to: Sophoridine induces apoptosis and S phase arrest via ROS-dependent JNK and ERK activation in human pancreatic cancer cells
por: Xu, Zihang, et al.
Publicado: (2020)

Correction: TMEM43 promotes pancreatic cancer progression by stabilizing PRPF3 and regulating RAP2B/ERK axis
por: Li, Junqiang, et al.
Publicado: (2023)

Correction to: High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin lymphoma
por: Swoboda, Ryszard, et al.
Publicado: (2021)

Calcium channel blockers potentiate gemcitabine chemotherapy in pancreatic cancer
por: Principe, Daniel R., et al.
Publicado: (2022)

Gold Nanoparticles sensitize pancreatic cancer cells to gemcitabine
por: Huai, Yanyan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_122542ccjvfg0btheq743dg5kc